Semax vs Selank: Structure and Neuropeptide Research Compared
For research purposes only. Not for human or veterinary use.
Semax and Selank are both synthetic heptapeptides, but they originate from different parent peptide sequences and are studied across different neuropeptide pathways. This guide examines their structural differences, research applications, and analytical verification.
1. Introduction
In the study of synthetic neuropeptides, Semax and Selank frequently emerge as subjects of comparative research. Both compounds are heptapeptides (consisting of seven amino acids) developed by the Institute of Molecular Genetics at the Russian Academy of Sciences. Despite their shared origin and similar peptide length, they are structurally distinct molecules derived from entirely different parent peptide sequences. Understanding these structural differences is essential for researchers investigating specific neurological pathways and selecting the appropriate compound from research peptide categories.
2. What Is Semax?
Semax is a synthetic analogue of the adrenocorticotropic hormone (ACTH). Specifically, it is described precisely as ACTH(4–7)-Pro-Gly-Pro, and is commonly described as an ACTH(4–10) analogue that has been structurally modified to enhance its stability against enzymatic degradation. The precise amino-acid sequence of Semax is Met-Glu-His-Phe-Pro-Gly-Pro. In laboratory research, Semax is primarily studied for its potential influence on neurotrophic factors. Animal studies have demonstrated that Semax can specifically bind to sites in the rat basal forebrain and subsequently increase the levels of brain-derived neurotrophic factor (BDNF) protein in that region [1].
3. What Is Selank?
Selank, conversely, is a synthetic analogue of the naturally occurring immunomodulatory peptide tuftsin. The exact amino-acid sequence of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Like Semax, Selank incorporates a Pro-Gly-Pro sequence at its C-terminus to provide metabolic stability. However, its primary research focus differs significantly. Selank is predominantly investigated for its potential interaction with the GABAergic system. In experimental models involving rats, Selank administration has been shown to alter the expression of numerous genes involved in neurotransmission, suggesting a mechanism associated with allosteric modulation of GABA receptors [2].
4. Semax vs Selank: Comparison Table
| Amino-acid sequence | Parent-peptide relationship | Primary research area | Experimental models represented in the literature | Evidence limitations | Analytical verification |
|---|---|---|---|---|---|
| Met-Glu-His-Phe-Pro-Gly-Pro | ACTH-derived sequence (ACTH 4-10 analogue) | Neurotrophic factor modulation (e.g., BDNF) | In-vitro cell cultures, animal models (rats), limited human functional connectivity studies | Predominantly preclinical; effects in controlled human populations require further extensive study | HPLC and LC-MS |
| Thr-Lys-Pro-Arg-Pro-Gly-Pro | Tuftsin-derived sequence analogue | Stress-response and GABAergic signalling models | Animal models (rats), limited human functional connectivity studies | Predominantly preclinical; mechanism of action in human neural pathways remains largely theoretical | HPLC and LC-MS |
5. Peptide Sequences and Structural Origins
The fundamental difference between these two compounds lies in their sequence and origin. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) derives its core structure from an ACTH-derived sequence, a hormone intimately involved in the hypothalamic-pituitary-adrenal (HPA) axis and stress response. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) originates from a tuftsin-derived sequence, a tetrapeptide associated with immune system function. The shared C-terminal sequence (Pro-Gly-Pro) in both peptides is a deliberate synthetic modification designed to inhibit degradation by exopeptidases, thereby extending the half-life of the peptides in experimental settings. This structural stabilisation is crucial for conducting prolonged observational studies in animal models, allowing researchers to observe sustained physiological responses that would be impossible with the rapidly degraded natural parent peptides.
6. Differences in Research Focus
Because of their different structural origins, Semax and Selank are utilised to investigate different neurochemical pathways. Research involving Semax often concentrates on its capacity to modulate neurotrophins. The observed increase in BDNF levels in the rat basal forebrain suggests potential applications in models studying synaptic plasticity and neuronal survival [1]. Selank research, however, frequently explores stress-response and GABAergic signalling models. Studies analysing gene expression in the frontal cortex of rats indicate that Selank affects genes related to GABA receptor subunits, transporters, and ion channels, pointing toward an interaction with inhibitory neurotransmitter systems [2]. Thus, their structural differences are associated with different research pathways, guiding investigators in their selection of the appropriate compound.
7. What the Current Evidence Can and Cannot Show
It is imperative to clearly distinguish the levels of evidence supporting the actions of Semax and Selank. The vast majority of mechanistic data derives from in-vitro assays and animal models (primarily rodents). While these studies provide valuable insights into receptor binding and gene expression changes, they do not directly translate to general human physiological claims. The experimental findings are specific to the controlled laboratory environments and animal populations studied. Researchers must exercise caution in extrapolating these preclinical results to broader applications, acknowledging the inherent limitations of the current evidence base and the necessity for rigorous, controlled human trials to substantiate broader claims.
8. Comparing Both Compounds in Controlled Research
While often studied separately, Semax and Selank have also been investigated simultaneously to compare their effects directly. For instance, a functional connectomic study employing resting-state fMRI in healthy human participants evaluated the effects of both peptides on whole-brain functional connectivity. The study identified both general and specific effects on functional connectivity between the right amygdala and the right temporal cortex following administration of either peptide compared to a placebo [3]. Such comparative studies are vital for delineating the distinct neural networks influenced by these structurally different compounds, often explored together in a Neuropeptide Research Bundle.
9. Identity, Purity and Batch Verification
The structural integrity of Semax and Selank is paramount for reliable research outcomes. Because they are both heptapeptides with similar molecular weights, precise analytical techniques are required to differentiate them and ensure purity. Reverse-phase HPLC can estimate chromatographic purity, while LC-MS supports identity by comparing the observed molecular mass with the expected value. Neither method alone proves the complete amino-acid sequence, content per vial, sterility or endotoxin status. Additional validated testing may be required. Researchers should always rely on comprehensive HPLC and mass spectrometry testing, alongside batch verification and COAs, to confirm the exact nature of their research materials before commencing experiments.
10. Storage and Laboratory Handling
As synthetic peptides, Semax and Selank are susceptible to degradation if not handled correctly. Storage conditions should follow the supplier’s validated stability data and the requirements of the particular laboratory protocol. Both peptides are sensitive to extreme temperatures, prolonged exposure to light, and mechanical stress, which may compromise peptide integrity. Reconstitution diluents should be chosen based on the specific requirements of the assay. For detailed instructions on maintaining compound viability, researchers should refer to a comprehensive peptide storage guide.
11. Frequently Asked Questions
Are Semax and Selank the same peptide?
No. While both are synthetic heptapeptides (seven amino acids long) developed by the same institute, they have different amino-acid sequences and originate from different parent peptide sequences (ACTH-derived and tuftsin-derived sequences, respectively).
How do their amino-acid sequences differ?
Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. They share only the stabilising C-terminal Pro-Gly-Pro sequence.
Are Semax and Selank studied across the same pathways?
While there is some overlap in their broad application to neural research, their primary research focus differs. Semax is primarily studied for its effects on neurotrophic factors like BDNF, whereas Selank is predominantly investigated for its interaction with stress-response and GABAergic signalling models and related neurotransmission genes.
Can both compounds be compared within one controlled study?
Yes. Comparative studies, such as functional MRI research in human participants, have been conducted to evaluate and contrast the specific effects of both Semax and Selank on brain functional connectivity.
How should their identity and purity be verified?
Identity and purity must be verified using high-performance liquid chromatography (HPLC) and mass spectrometry. Reverse-phase HPLC can estimate chromatographic purity, while LC-MS supports identity by comparing the observed molecular mass with the expected value.
12. Conclusion
Semax and Selank represent two distinct avenues of neuropeptide research. While they share a structural stabilisation strategy, their structural differences are associated with different research pathways in experimental models. Understanding these distinctions is critical for the rigorous design and interpretation of laboratory studies. Explore ZENTRA’s batch-verified Semax, Selank and Neuropeptide Research Bundle, supplied exclusively for laboratory research, in our research peptide catalogue.
Sources and References
- [1] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Y. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of neurochemistry, 97 Suppl 1, 82–86. https://pubmed.ncbi.nlm.nih.gov/16635254/
- [2] Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in pharmacology, 7, 31. https://pubmed.ncbi.nlm.nih.gov/26924987/
- [3] Panikratova, Y. R., Lebedeva, I. S., Sokolov, O. Y., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady. Biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 490(1), 9–11. https://pubmed.ncbi.nlm.nih.gov/32342318/
For guidance on evaluating UK research materials and analytical documentation, see our UK research peptide verification guide.
For research purposes only. Not for human or veterinary use.
